Increased circulating RANTES in type 2 diabetes

European Cytokine Network

Volumn 25, Issue 3, 2014, Pages 46-51

  Dworacka, Marzena ^a   KrzyŻagórska, Ewa ^b   Iskakova, Saule ^c   Bekmukhambetov, Yerbol ^c   Urazayev, Olzhas ^c   Dworacki, Grzegorz ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b Poznan Specialist Center of Medical Care   (Poland)

^c Department of Pharmacology Marat Ospanov University of Medical Sciences ^*  (Kazakhstan)

Author keywords

1; 5 anhydro D glucitol; Postprandial hyperglycaemia; RANTES; Type 2 diabetes

Indexed keywords

1, 5 ANHYDROSORBITOL; ACETYLSALICYLIC ACID; C PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HEMOGLOBIN A1C; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; RANTES; SARTAN DERIVATIVE; UNCLASSIFIED DRUG; 1,5-ANHYDROGLUCITOL; CCL5 PROTEIN, HUMAN; DEOXYGLUCOSE; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; AGE; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERGLYCEMIA; INFLAMMATION; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OHKURA INDEX; POSTPRANDIAL STATE; PROTEIN EXPRESSION; SCORING SYSTEM; STABLE ANGINA PECTORIS; WAIST CIRCUMFERENCE; BLOOD; CASE CONTROL STUDY; GLUCOSE BLOOD LEVEL; METABOLISM; PHYSIOLOGY;

BLOOD GLUCOSE; CASE-CONTROL STUDIES; CHEMOKINE CCL5; DEOXYGLUCOSE; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HOMOCYSTEINE; HUMANS; HYPERGLYCEMIA; INSULIN RESISTANCE; MIDDLE AGED;

EID: 84908615461     PISSN: 11485493     EISSN: 19524005     Source Type: Journal    
DOI: 10.1684/ecn.2014.0355     Document Type: Article

References (43)

1. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 2012; 32: 2045-51.
2. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444: 860-7.
3. Blake GJ, Ridker PM. Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med 2002; 252: 283-94.
4. Matter CM, Handschin C. RANTES (regulated on activation, normal T cell expressed and secreted), inflammation, obesity, and the metabolic syndrome. Circulation 2007; 115: 946-8.
5. Schober A. Chemokines in vascular dysfunction and remodeling. Arterioscler Thromb Vasc Biol 2008; 28: 19509.
6. Aukrust P, Halvorsen B, Yndestad A, et al. Chemokines and Cardiovascular Risk. Arterioscler Thromb Vasc Biol 2008; 28: 1909-19.
7. Virani SS, Nambi V, Hoogeveen R, et al. Relationship between circulating levels of RANTES (regulated on activation, normal T-cell expressed, and secreted) and carotid plaque characteristics: the Atherosclerosis Risk in Communities (ARIC) carotid MRI study. Eur Heart J 2011; 32: 459-68.
8. Zernecke A, Shagdarsuren E, Weber C. Chemokines in atherosclerosis: an update. Arterioscler Thromb Vasc Biol 2008; 28: 1897-908.
9. Herder C, Peeters W, Illig T, et al. RANTES/CCL5 and risk for coronary events: results from the MONICA/KORA Augsburg case-cohort, Athero-Express and CARDIoGRAM studies. PLoS One 2011; 6: e25734.
10. Herder C, Haastert B, Müller-Scholze S, et al. Association of systemic chemokine concentrations with impaired glucose tolerance and type 2 diabetes: results from the Cooperative Health Research in the Region of Augsburg Survey S4 (KORA S4). Diabetes 2005; 54(Suppl 2): S11-7.
11. Eringa EC, Serne EH, Meijer RI, et al. Endothelial dysfunction in (pre)diabetes: characteristics, causative mechanisms and pathogenic role in type 2 diabetes. Rev Endocr Metab Disord 2013; 14: 39-48.
12. Gerich JE. Clinical significance, pathogenesis, and management of postprandial hyperglycemia. Arch Intern Med 2003; 163: 1306-16.
13. Dworacka M, Winiarska H. The application of plasma 1,5-anhydro-D-glucitol (1,5-AG) for monitoring type 2 diabetic patients. Dis Markers 2005; 21: 127-32.
14. Won JC, Park CY, Park HS, et al. 1,5-Anhydroglucitol reflects post-prandial hyperglycemia and a decreased insulinogenic index, even in subjects with prediabetes and well-controlled type 2 diabetes. Diabetes Res Clin Pract 2009; 84: 51-7.
15. Yamanouchi T, Akanuma Y. Serum 1,5-anhydroglucitol (1,5 AG): new clinical marker for glycemic control. Diabetes Res Clin Pract 1994; 24(Suppl): S261-8.
16. Dworacka M, Winiarska H, Szymanska M, Kuczynski S, Szczawinska K, Wierusz-Wysocka B. 1,5-Anhydro-D-glucitol: a novel marker of glucose excursions. Intern J Clin Prac 2002; Suppl 129: 40-4.
17. Festa A, D’Agostino RJr A, Tracy RP, Haffner SM. C-reactive protein is more strongly related to post-glucose in non-diabetic subjects: the Insulin Resistance Atherosclerosis Study. Diabet Med 2002; 19: 939-42.
18. Herder C, Illig T, Baumert J, et al. RANTES/CCL5gene polymer-phisms, serum concentrations, and incident type 2 diabetes: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Eur J Endocrinol 2008; 158: R1-5.
19. Huber J, Kiefer FW, Zeyda M, et al. CC chemokine and CC chemokine receptors profiles in visceral and subcutaneous adipose tissue are altered in human obesity. J Clin Endocrinol Metab 2008; 93: 3215-21.
20. Abdella NA, Mojiminiyi OA, Akanji AO, Moussa MA. Associations of plasma homocysteine concentration in subjects with type 2 diabetes mellitus. Acta Diabetologica 2002; 39: 183-90.
21. Lawrence de Koning AB, Werstuck GH, Zhou J, Austin RC. Hyperhomocysteinemia and its role in the development of atherosclerosis. Clin Biochem 2003; 36: 431-41.
22. Sun W, Wang G, Zhang ZM, Zeng XK, Wang X. Chemokine RANTES is upregulated in monocytes from patiens with hyperhomocysteinemia. Acta Pharmacol Sin 2005; 26: 1317-21.
23. Inzucchi SE, Bergenstal RM, Buse JB, et al, American Diabetes Association (ADA) JB, European Association for the Study of Diabetes (EASD) JB. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-79.
24. Ohkura T, Shiochi H, Fujioka Y, et al. 20/(fasting C-peptide × fasting plasma glucose) is a simple and effective index of insulin resistance in patients with type 2 diabetes mellitus: a preliminary report. Cardiovasc Diabetol 2013; 12: 12.
25. Chusney GD, Philippa M, Pickup JC. Comparison of micro-enzymatic and high performance liquid chromatographic methods for the assay of serum 1,5-anhydroglucitol. Clin Chim Acta 1995; 235: 91-9.
26. Weykamp C, John WG, Mosca A, et al. The IFCC Reference Measurement System for HbA1c: A 6-Year Progress Report. Clin Chem 2008; 2: 240-8.
27. Huo Y, Schober A, Forlow SB, Smith DF, Hyman MC, Jung S, Littman DR, Weber C, Ley K. Circulating activated platelets exacer-bate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 2003; 9: 61-7.
28. Koenen RR, von Hundelshausen P, Nesmelova IV, Zernecke A, Liehn EA, Sarabi A, Kramp BK, Piccinini AM, Paludan SR, Kowalska MA, Kungl AJ, Hackeng TM, Mayo KH, Weber C. Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. Nat Med 2009; 15: 97-103.
29. Veillard NR, Kwak B, Pelli G, et al. Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice. Circ Res 2004; 94: 253-61.
30. Kraaijeveld AO, de Jager SC, de Jager WJ, et al. CC chemokine ligand-5 (CCL5/RANTES) and CC chemokine ligand-18 (CCL18/PARC) are specific markers of refractory unstable angina pectoris and are transiently raised during severe ischemic symptoms. Circulation 2007; 116: 1931-41.
31. Arkan MC, Hevener AL, Greten FR, et al. IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med 2005; 11: 191-8.
32. Cai D, Yuan M, Frantz DF, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NFkappaB. Nat Med 2005; 11: 183-90.
33. Tourniaire F, Romier-Crouzet B, Lee JH, et al. Chemokine expression in inflamed adipose tissue is mainly mediated by NF-B. PLoS One 2013; 8: e66515.
34. Frostegård J. Immune mechanisms in atherosclerosis, especially in diabetes type 2. Front Endocrinol (Lausanne) 2013; 4: 162.
35. Humphrey LL, Fu R, Rogers K, Freeman M, Helfand M. Homocys-teine level and coronary heart disease incidence: a systematic review and meta-analysis. Mayo Clin Proc 2008; 83: 1203-12.
36. Holmer-Jensen J, Karhu T, Mortensen LS, Pedersen SB, Herzig KH, Hermansen K. Differential effects of dietary protein sources on postprandial low-grade inflammation after a single high fat meal in obese non-diabetic subjects. Nutr J 2011; 10: 115.
37. Peter R, Okoseime OE, Rees A, Owens DR. Postprandial glucose-a potential therapeutic target to reduce cardiovascular mortality. Curr Vasc Pharmacol 2009; 7: 68-74.
38. The DECODE Study Group, the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001; 161: 397-405.
39. Bonora E. Postprandial peaks as a risk factor for cardiovascular disease: epidemiological perspectives. Int J Clin Pract 2002; Suppl.129: 5-11.
40. Cederberg H, Saukkonen T, Laakso M, et al. Postchallenge glucose. A1C, and fasting glucose as predictors of type 2 diabetes and cardio-vascular disease: a 10-year prospective cohort study. Diabetes Care 2010; 33: 2077-83.
41. Monnier L, Colette C, Owens DR. Integrating glycaemic vari-ability in the glycaemic disorders of type 2 diabetes: a move towards a unified glucose tetrad concept. Diabetes Metab Res Rev 2009; 25: 393-402.
42. Ceriello A, Davidson J, Hanefeld M, et al, International Prandial Glucose Regulation Study Group M. Postprandial hyperglycaemia and cardiovascular complications of diabetes: an update. Nutr Metab Cardiovasc Dis 2006; 16: 453-6.
43. Watanabe M, Kokubo Y, Higashiyama A, et al. Serum 1,5-anhydro-D-glucitol levels predict first-ever cardiovascular disease: an 11-year population-based cohort study in Japan, the Suita study. Atherosclerosis 2011; 216: 477-83.